s2 

PEPTIDE HORMONES, GROWTHFACTORS, RELATED SUBSTANCES ANDMIMETICS

ALL TIMES

– All prohibited substances in this class are non-Specified Substances.

The following substances, and other substances with similar chemical
structure or similar biological effect(s), are prohibited:
S2.1. ERYTHROPOIETINS (EPO) AND AGENTS AFFECTING
ERYTHROPOIESIS, INCLUDING, BUT NOT LIMITED TO:
S2.1.1 ERYTHROPOIETIN-RECEPTOR AGONISTS, E.G.
o Darbepoetins (dEPO)
o Erythropoietins (EPO)
o EPO-based constructs [e.g. EPO-Fc, methoxy polyethylene
glycol-epoetin beta (CERA)]
o EPO-mimetic agents and their constructs (e.g. CNTO-530,
peginesatide).
S2.1.2 HYPOXIA-INDUCIBLE FACTOR (HIF) ACTIVATING AGENTS,
E.G.

o Cobalt
o Daprodustat (GSK1278863)
o IOX2
o Molidustat (BAY 85-3934)
o Roxadustat (FG-4592)
o Vadadustat (AKB-6548)
o Xenon
S2.1.3 GATA INHIBITORS, E.G.
o K-11706
S2.1.4 TRANSFORMING GROWTH FACTOR -BETA (TGF-Β)
SIGNALING INHIBITORS, E.G.
o Luspatercept
o Sotatercept
S2.1.5 INNATE REPAIR RECEPTOR AGONISTS, E.G.
o Asialo EPO
o Carbamylated EPO (CEPO)
S2.2. PEPTIDE HORMONES AND THEIR RELEASING FACTORS
S2.2.1 TESTOSTERONE-STIMULATING PEPTIDES IN MALES
INCLUDING, BUT NOT LIMITED TO:
o chorionic gonadotrophin (CG)
o luteinizing hormone (LH) 
o gonadotrophin- releasing hormone (GnRH, gonadorelin) and its
agonist analogues (e.g. buserelin, deslorelin, goserelin, histrelin,
leuprorelin,
nafarelin and triptorelin)
o kisspeptin and its agonist analogues
S2.2.2 CORTICOTROPHINS AND THEIR RELEASING FACTORS,
E.G. CORTICORELIN AND TETRACOSACTIDE
S2.2.3 GROWTH HORMONE (GH), ITS ANALOGUES AND
FRAGMENTS, INCLUDING, BUT NOT LIMITED TO:

o growth hormone analogues, e.g. lonapegsomatropin,
somapacitan and somatrogon
o growth hormone fragments, e.g. AOD-9604 and hGH 176-191
S2.2.4 GROWTH HORMONE RELEASING FACTORS, INCLUDING,
BUT NOT LIMITED TO:
o growth hormone-releasing hormone (GHRH) and its analogues
(e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin)
o growth hormone secretagogues (GHS) and their mimetics [e.g.
anamorelin, capromorelin, ibutamoren (MK-677), ipamorelin,
lenomorelin (ghrelin), macimorelin and tabimorelin]
o GH-releasing peptides (GHRPs) [e.g. alexamorelin, examorelin
(hexarelin), GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4,
GHRP-5 and GHRP-6]
S2.3. GROWTH FACTORS AND GROWTH FACTOR MODULATORS
INCLUDING, BUT NOT LIMITED TO:
o Fibroblast growth factors (FGFs)
o Hepatocyte growth factor (HGF)
o Insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues
o Mechano growth factors (MGFs)
o Platelet-derived growth factor (PDGF)
o Thymosin-β4 and its derivatives e.g. TB-500
o Vascular endothelial growth factor (VEGF)
and other growth factors or growth factor modulators affecting
muscle, tendon or ligament protein synthesis/degradation,
vascularisation, energy utilization, regenerative capacity or fibre
type switching.